Evidence map›Paper›PMID 26759315›Full record

ArticleInternational journal of clinical oncology2016

Frequency of level II and III axillary nodes metastases in patients with positive sentinel lymph nodes in melanoma: a multi-institutional study in Japan.

Arata Tsutsumida, Akira Takahashi, Kenjiro Namikawa, Naoya Yamazaki, Hisashi Uhara, Yukiko Teramoto, Tatsuya Takenouchi, Satoshi Fukushima, Kenji Yokota, Jiro Uehara and 7 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Current surgical management for melanoma.The Journal of dermatology · 2024
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 1 country.

Arata TsutsumidaDepartment of Dermatologic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan. atsutsum@ncc.go.jp.
Akira TakahashiDepartment of Dermatologic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan.
Kenjiro NamikawaDepartment of Dermatologic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan.
Naoya YamazakiDepartment of Dermatologic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan.
Hisashi UharaDepartment of Dermatology, Shinshu University, Matsumoto, Japan.
Yukiko TeramotoDepartment of Skin Oncology and Dermatology, Saitama Medical University, International Medical Center, Hidaka, Japan.
Tatsuya TakenouchiDepartment of Dermatology, Niigata Cancer Center Hospital, Niigata, Japan.
Satoshi FukushimaDepartment of Dermatology and Plastic Surgery, Kumamoto University, Kumamoto, Japan.
Kenji YokotaDepartment of Dermatology, Nagoya University, Nagoya, Japan.
Jiro UeharaDepartment of Dermatology, Asahikawa Medical University, Asahikawa, Japan.
Shigeto MatsushitaDepartment of Dermato-Oncology/Dermatology, Kagoshima Medical Center and Department of Dermatology, Kagoshima University, Kagoshima, Japan.
Yoshitsugu ShibayamaDepartment of Dermatology, Fukuoka University, Fukuoka, Japan.
Naohito HattaDepartment of Dermatology, Toyama Prefectural Central Hospital, Toyama, Japan.
Yuri MasuiDepartment of Dermatology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Hiroshi UchiDepartment of Dermatology, Kyushu University, Fukuoka, Japan.
Yasuhiro FujisawaDepartment of Dermatology, University of Tsukuba, Tsukuba, Japan.
Dai OgataDepartment of Dermatology, Saitama Medical University, Moroyama, Japan.
Saitama Medical University · JPAsahikawa Medical University · JPFukuoka University · JPKagoshima Medical Center · JPKumamoto University · JPKyushu University · JPNagoya University · JPNiigata Cancer Center Hospital · JPŌtani University · JPThe University of Tokyo · JPToyama Prefectural Central Hospital · JPUniversity of Tsukuba · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAxillary lymph node dissection (ALND) has been recommended to include levels I-III for melanoma patients who have evidence of metastasis in the axillary sentinel lymph node (SLN). The extent of the subsequent axillary dissection is in debate. The objective of this study was to determine the frequency of metastasis of level III nodes in addition to that of level II nodes in this setting.

methodsA multi-institutional retrospective study was undertaken in 14 melanoma treatment centers in Japan.

resultsBetween 2007 and 2012, 69 patients with involved axillary SLNs underwent a subsequent ALND and 55 underwent level I and II dissections. Level III metastatic nodes, which is our primary endpoint, were seen in only 1 patient (1.5 %). The level II metastatic rate was 4.4 %.

conclusionsOur study sample size was small, but melanoma patients with positive SLN rarely had level III disease, suggesting that level III dissection may be unnecessary. We also found that level II metastasis was not so frequent. More evidence is needed to standardize the extent of ALND and to identify the patients who would have the most benefit with undergoing level II dissection for positive axillary SLNs.

Indexed as

Lymph Node ExcisionSentinel Lymph Node BiopsyAdultAgedAged, 80 and overAxillaFemaleHumansIncidenceJapanLymphatic MetastasisMaleMelanomaMiddle AgedNeoplasm StagingRetrospective StudiesAxillaLymphadenectomyLymph node dissectionMelanomaSentinel lymph node

Identifiers

PMID26759315
OpenAlexW2232954565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.